|
[1]
|
Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer. version 2.2013[J]. J Natl Compr Canc Netw, 2013, 11(6):645-653. http://d.old.wanfangdata.com.cn/Periodical/zhfszl201303008
|
|
[2]
|
Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer[J]. N End J Med, 2010, 363(18):1693-1703. doi: 10.1056-NEJMoa1006448/
|
|
[3]
|
Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizolinib in untreated ALK-positive non-Small-cell lung cancer[J]. N Engl J Med, 2017, 377(9):829-838.
|
|
[4]
|
Guerin A, Sasane M, Zhang J, et al. Brain metastases in patients with ALK+ non-small cell lung cancer:clinical symptoms, treatment patterns and economic burden[J]. J Med Econ, 2015, 18(4):312-322. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.3111/13696998.2014.1003644
|
|
[5]
|
Rangachari D, Yamaguchi N, VanderLaan PA, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers[J]. Lung Cancer, 2015, 88(1):108-111. http://d.old.wanfangdata.com.cn/Periodical/zhblx201411008
|
|
[6]
|
Sperduto PW, Yang TJ, Beal K, et al. Estimating survival in patients with lung cancer and brain metastases:an update of the graded prognostic assessment for lung cancer using molecular markers (lung-molGPA)[J]. JAMA Oncol, 2017, 3(6):827-831. http://cn.bing.com/academic/profile?id=f61d56916cc98761d93509f20ef48e20&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[7]
|
Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene ALK to a nucleolar protein gene NPM in non-Hodgkin's lymphoma[J]. Science, 1994, 263(5151):1281-1284. http://cn.bing.com/academic/profile?id=be77d6edb08d938a0dd470195846d789&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[8]
|
Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML-ALK fusion gene in non-small-cell lung cancer[J]. Nature, 2007, 448(7153):561-566. https://www.nature.com/articles/nature05945
|
|
[9]
|
Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology[J]. Nat Rev Cancer, 2013, 13(10):685-700. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=193e4cc989475ea817bc76d35c80afc7
|
|
[10]
|
Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer[J]. Clin Cancer Res, 2009, 15(9):3143-3149. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=5f991d41971d641ca95879de3e0a301b
|
|
[11]
|
Masters GA, Temin S, Azzoli CG, et al. American society of clinical oncology clinical practice. systemic therapy for stage Ⅳ non-small-cell lung cancer:american society of clinical oncology clinical practice guideline up-date[J]. J Clin Oncol, 2015, 33(30):3488-3515. doi: 10.1056/NEJMoa1713137
|
|
[12]
|
Novello S, Barlesi F, Califano R, et al. ESMO Guidelines Committee. Metastatic non-small-cell lung cancer:ESMO clinical practice guide-lines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2016, (27 suppl 5):v1-27.
|
|
[13]
|
Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer[J]. N Engl J Med, 2014, 371(23):2167-2177. http://cn.bing.com/academic/profile?id=3ff2ee2ced618fea99c3588db613e765&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[14]
|
Costa DB, Shaw AT, Ou SH, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases[J]. J Clin Oncol, 2015, 33(17):1881-1888. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=b03b21ac773627e1567825acd6dd8a44
|
|
[15]
|
Metro G, Lunardi G, Floridi P, et al. CSF Concentration of crizotinib in two ALK-positive non-small-cell lung cancer patients with CNS metastases deriving clinical benefit from treatment[J]. J Thorac Oncol, 2015, 10(5):e26-e27. http://med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_PM26380734
|
|
[16]
|
Kim S, Kim TM, Kim DW, et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK rearranged lung cancer[J]. J Thorac Oncol, 2013, 8(4):415-422. http://cn.bing.com/academic/profile?id=0f025f56f14694befe4c0abd34678f2a&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[17]
|
Marsilje TH, Pei W, Chen B, et al. Synthesis, structure-activity relationship, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloroN2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl) pyrimidine-2, 4-diamine (LDK378) currently in phase 1 and 2 clinical trials[J]. J Med Chem, 2013, 56(14):5675-5690. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM23742252
|
|
[18]
|
Crinò L, Ahn MJ, De Marinis F, et al. Multicenter phase Ⅱ study of whole-body and intracranial activity with ceritinib in patients with ALKrearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib:results from ASCEN D-2[J]. J Clin Oncol, 2016, 34(24):2866-2873. https://www.researchgate.net/publication/305419370_Multicenter_Phase_II_Study_of_Whole-Body_and_Intracranial_Activity_With_Ceritinib_in_Patients_With_ALK-Rearranged_Non-Small-Cell_Lung_Cancer_Previously_Treated_With_Chemotherapy_and_Crizotinib_Results
|
|
[19]
|
Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinumbased chemotherapy in advanced ALK-rearranged non-somall-cell lung cancer (ASCEND-4):a randomised, open-label, phase 3 study[J]. Lancet, 2017, 389(10072):917-929. https://www.researchgate.net/publication/312641343_First-line_ceritinib_versus_platinum-based_chemotherapy_in_advanced_ALK-rearranged_non-small-cell_lung_cancer_ASCEND-4_A_randomised_open-label_phase_3_study
|
|
[20]
|
Cho BC, Obermannova R, Bearz A, et al. Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-positive NSCLC:primary efficacy results from the ASCEND-8 study[J]. J Thorac Oncol, 2019, 14(7):1255-1265.
|
|
[21]
|
Kodama T, Tsukaguchi T, Yoshida M, et al. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance[J]. Cancer Lett, 2014, 351(2):215-221. http://cn.bing.com/academic/profile?id=fa7c647f4ead1dfcef27908b5e560407&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[22]
|
Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinibresistant, non-small-cell lung cancer:a single-group, multicentre, phase 2 trial[J]. Lancet Oncol, 2016, 17(2):234-242. https://www.ncbi.nlm.nih.gov/pubmed/26708155/
|
|
[23]
|
Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer[J]. N Engl J Med, 2017, 377(9):829-838. http://cn.bing.com/academic/profile?id=86c652cfd9d16613df3c532ec9483c7a&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[24]
|
Ettinger DS, Aisner DL, Wood DE, et al. NCCN guidelines insights:nonsmall cell lung cancer, version 5.2018[J]. J Natl Compr Cancer Netw, 2018, 16(7):807-821. http://d.old.wanfangdata.com.cn/Periodical/dgyx201806010
|
|
[25]
|
Katayama R, Sakashita T, Yanagitani N, et al. P-glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged nonsmall cell lung cancer[J]. EBiomedicine, 2016, 12(3):54-66. https://www.ncbi.nlm.nih.gov/pubmed/26870817
|
|
[26]
|
Seto T, Kiura K, Nishio M, et al. CH5424802(RO5424802) for patients with ALK-rearran-ged advanced non-small-cell lung cancer (AF-001JP study):a single-arm, open-label, phase 1-2 study[J]. Lancet Oncol, 2013, 14(7):590-598.
|
|
[27]
|
Gadgeel S, Shaw AT, Barlesi F, et al. Cumulative incidence rates for CNS and non-CNS progression in two phase Ⅱ studies of alectinib in ALKpositive NSCLC[J]. Br J Cancer, 2018, 118(1):38-42.
|
|
[28]
|
Novello S, Mazières J, Oh IJ, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive nonsmall-cell lung cancer:results from the phase Ⅲ ALUR study[J]. Ann Oncol, 2018, 29(6):1409-1416. https://www.ncbi.nlm.nih.gov/pubmed/29668860
|
|
[29]
|
Nishio M, Nakagawa K, Mitsudomi T, et al. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALKpositive non-small-cell lung cancer[J]. Lung Cancer Amst Neth, 2018, 121:37-40. https://www.sciencedirect.com/science/article/pii/S016950021830343X
|
|
[30]
|
Gettinger SN, Bazhenova LA, Langer CJ, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies:a single-arm, open-label, phase 1/2 trial[J]. Lancet Oncol, 2016, 17(12):1683-1696. http://cn.bing.com/academic/profile?id=096be784389b0a4fa50276263dcc5897&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[31]
|
Camidge R, Kim D, Tiseo DW, et al. Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive nonsmall-cell lung cancer and brain metastases in two clinical trials[J]. JCO, 2018, 36(26):2693-2701. https://www.ncbi.nlm.nih.gov/pubmed/29768119
|
|
[32]
|
Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10R)-7-amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4-(metheno)pyrazolo[4, 3-h][2, 5, 11]-benzox-adiazacyclotetradecine-3-carbonitrile(PF-06463922), a macroc-yclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1(ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations[J]. J Med Chem, 2014, 57(11):4720-4744.
|
|
[33]
|
Friboulet L, Zou H, Kodack DP, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to 1st and 2nd generation ALK inhibitors in preclinical models[J]. Cancer Cell, 2015, 28(1):70-81. https://www.sciencedirect.com/science/article/pii/S1535610815001865
|
|
[34]
|
Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement:an international, multicentre, open-label, single-arm first-in-man phase 1 trial[J]. Lancet Oncol, 2017, 18(12):1590-1599. http://d.old.wanfangdata.com.cn/Periodical/xzyx201801014
|
|
[35]
|
Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALKpositive non-small-cell lung cancer:results from a global phase 2 study[J]. Lancet Oncol, 2018, 19(12):1654-1667. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30649-1/fulltext
|
点击查看大图
下载:
